NVS vs TAK
Novartis AG vs Takeda Pharmaceutical Company Limited — AI-powered side-by-side comparison
VS
TAK
Takeda Pharmaceutical Company Limited
67
Insufficient Data
| Metric | NVS | TAK |
|---|
| AI Score |
75
|
67
|
| Price |
$154.64
|
$17.49
|
| P/E Ratio |
23.55×
|
48.87×
|
| ROE |
30.5%
|
2.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
74.3%
|
62.1%
|
| Debt / Equity |
1.18×
|
0.65×
|
| Dividend Yield |
2.9%
|
3.6%
|
| RSI (14) |
57.7
|
61.6
|
| Beta |
0.462
|
0.088
|
| Expected Upside |
+2.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for NVS versus TAK.
NVS leads by 8 points.
NVS scores 75/100 (Buy) versus TAK at 67/100 (Insufficient Data).
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
TAK Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical